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1. Introduction 
Human immunodeficiency virus type 1 (HIV-1) infection with more than one strain, 
termed dual infection (DI), encompasses both co and superinfection (SI). Co-infection is 
the acquisition of two viral strains during primo-infection, whereas SI is the infection with 
a second heterologous strains after primary infection or during the course of an 
established infection.  
The first evidence that support HIV-1 DI, is the existence of numerous circulanting 
recombinant forms, because recombination requires that a single cell is infected by two 
viruses. Recombination could arise inter-subtype (where viruses differ by ~30% in the viral 
envelope sequence) and intra–subtype (where viruses differ by only ~10% in the envelope). 
The first case of a intersubtype SI in a man, infected with a CRF01-AE recombinant form, 
who became superinfected with a subtype B strain was described by (Jost et al., 2002). 
Similar inter subtype cases have been reported by (Ramos et al., 2002). Intrasubtype cases, 
where the first and the second strain belong to the same B subtype, have been described  
(Altfeld et al., 2002; Pernas et al., 2006).  
2. Detection 
Different methods have been used to detect DI: restriction fragment length polymorphism 
(RFLP) (Ramos et al., 2002), multiregion hybridization assay (MHA), heteroduplex tracking 
assay (HTA), hetroduplex mobility assay (HMA) (Manigart et al., 2004), sequencing of single 
copy PCR amplifications (Salazar-Gonzalez et al., 2008), clonal sequencing followed by 
phylogenetic analysis (Pernas et al., 2006). All these methods are expensive, time consuming 
and require a laborious analysis.  
Recently, new approaches to detect SI have been developed. Within population–based 
sequences multiple nucleotides are possible at a single position,  which is called ambiguity 
codes. The presence of high number of ambiguous codes in the Viro-Seq HIV-RT sequence, 
vastly used for routine determination of resistance-associated mutations, has been applied 
to detect DI. In 16 out 37 patients, the existence of more than 34 ambiguous sites (34-99) in 
the Viro-Seq HIV-RT sequence revealed new cases of dual infections (Cornelissen et al., 
2007). However, this method was less sensitive when compared to HMA (Rachinger et al., 
2010) since minor variants present below 20-30% in the quasispecies population could not be 
detected in the sequence chromatogram. Because non synonymous positions are selected by 
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immune response or HAART, a new method focused on mixtures only in the synonymous 
positions (SM-index) was applied to discriminate between dually and single infection in 
highly-risk patients. To confirm the cases of DI, ultra-deep sequencing (UDS) was compared 
to the single genome sequence (SGS) method, considered as the gold standard method. In 
most of the samples, UDS identified minority variants that were not detected by SGS. Only 
in samples with very low viral load, SGS could detect minority variants more accurately 
than the UDS. These results showed that UDS could eventually replace SGS as the method 
for DI screening (Pacold et al., 2010). 
The study of HIV-1 SI is highly dependent on the availability of the appropriate samples. 
Due to the high recombination rate in HIV (Jost et al., 2002), it is necessary to have samples 
close to the SI event, because after SI, recombinant strains could arise and mask the 
phylogenetic segregation of the clades. Serial sampling permits the detection of SI because it 
allows the identification of the resident strain; detect the appearance of the new strain and 
the emergence of recombinant strains (Gerhard M. Mloka, 2004; Pernas et al., 2006). 
Sometimes, soon after SI one of the virus strains overgrow the other which could no longer 
be detected (Templeton et al., 2009), and also the expression of one strain can vary with time 
(Kozaczynska et al., 2007; McCutchan et al., 2005).  
Analysis of a second region in the HIV genome, that has permitted the detection of new 
cases of DI (Piantadosi et al., 2008),  should be considered a standard approach for HIV SI 
detection. 
We analyzed SI in an HIV-1 infected patient showing high-risk practices (Pernas et al., 2006). 
Viral quasispecies were analyzed in pol and env genes in several plasma samples during the 
patient follow up. Analysis in env gene confirmed the existence of 3 different strains in the 
viral population, one of them a recombinant (Figure 1). The analysis of serial samples as 
well as the analysis of a second genomic region in env gene (Figure 1) has permitted the 
detection of SI and the identification of recombinant variants.  
One important issue is how to discriminate between co-infection and SI. SI implies that the 
second infection can occur after the development of an immune response, suggesting that 
natural infection does not provide enough protection against SI; whereas co-infection occurs 
during primoinfection while the immune response is still not completely functional. To 
distinguish between these two events, the analysis of sequential samples is necessary. 
However it is not always possible.  
In our group, we developed a method that permits the estimation of the dating time of 
viruses (Casado et al., 2000). The viral dating time is estimated by the use of a linear-
correlation equation,  previously developed on the basis of a large set of Spanish samples, 
that correlates the V3 nucleotide-sequence divergence to the Spanish-epidemic MRCA with 
the sampling time. Using this approach (Casado et al., 2007) we interpolated the year of the 
nucleotide sequence of each of the different patient clades (Table 1), were able to 
discriminate between co-infection and a SI in two LTNPs patients, supporting the usefulness 
of the viral dating methodology. The years calculated for clades a and b for patient 1 were 
identical (1992), whereas those obtained for clades a and b for patient 2 was 1987 for clade a, 
close to the seroconversion time, and 1996 for cluster b (9 years later). The viral dating 
indicates that a SI had occurred in patient 2, whereas analysis of the first sample from 
patient 1 showed that he already was coinfected, although a previous SI could not be ruled 
out. 
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Fig. 1. A). Maximum likehood tree of the sequence quasispecies derived from the C2-C5 
region (501 nt) in the env gene. Clones were obtained at different time points 4-99♦, 7-99●, 
6-00■ and 10-03■. Brackets in the right hand of the phylogenetic tree group the sequences 
corresponding to a , b and recombinant strain (?). Samples included as external group are 
designed by letters. B) Bootscan plot in the same env region of the virus marked with an ? in 
panel A. Main strain (▬) and recombinant strain  (⋯) and external group (▬) are included 
in the analysis. In the first 240 nt the (?) virus showed an homology below 70% with the 
three compared viruses. C) Maximum likehood tree of the first 240 nt from the C2-C5 region 
in the env. Brackets in the right hand of the phylogenetic tree correspond to a , b and 
recombinant  (c?) virus. Samples designed with letters are reference Spanish strains. Bar 
represents 10 % genetic distance. 
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First
HIV-1+Test documented (year)
Genetic Distance to
Spanish MRCA
Viral  Dating
PATIENT
1
1986 6.9% ± 0.020% (a)
6.9% ± 0.019% (b)
1992 ± 3 (a)
1992 ± 3 (b)
PATIENT
2
1988 3.6% ± 1.4% (a)
9.2% ± 2.3% (b)
1987 ± 2 (a)
1996 ± 4 (b)
 
 
Table 1. Viral dating of dual infected LTNP patients. 
3. Incidence 
Although it is well establish that SI is frequent in HIV natural history, incidence studies 
have yielded contradictory results. Several studies found no evidence of HIV-1 SI, in a 
cohort of 718 HAART treated patients (Gonzales et al., 2003) nor in 37 injecting drug user 
patients who reported a high risk behaviour (Tsui et al., 2004).  In contrast, three population-
based studies found SI rates of ~5% which is similar to the primoinfection rate (Chohan et 
al., 2005). Other authors (Piantadosi et al., 2008) have found higher percentages of 7.7% per 
year, or even higher (17%) among 36 individuals (Piantadosi et al., 2007).  
Super-infection has been reported in every risk group, including men who have sex with 
men (MSM) (Campbell et al., 2009), heterosexual women (Templeton et al., 2009), and 
injection drug users (IDU) (Ramos et al., 2002; Yerly et al., 2004). Several cases of SI 
involving drug-resistant HIV-1 strains have been described (Ramos et al., 2002). Patients, 
inially infected with a drug-sensitive virus, has been superinfected with a resistant strain 
(Pernas et al., 2006; Smith et al., 2005) and vice versa (Koelsch et al., 2003). In another case, 
both viruses were drug-resistant (Brenner et al., 2004). 
4. SI and immune response 
Study about the role of the immune response in SI is limited. It is still unclear whether only 
the subset of individuals with a poor immune response are superinfected, or whether 
immune response during HIV-1 infection is in general inadequate to prevent infection. If SI 
is a common event, this implies that the immune response generated against HIV infection 
is not completely protective (Chohan, Piantadosi, and Overbaugh, 2010). 
4.1 CTL response 
SI has been observed in an individual who showed a cytotoxic acitvity (CTL) against the 
initial strain, but this response did not protect for SI with a second virus of the same (Altfeld 
et al., 2002) or different subtype (Ramos et al., 2002). Another case of SI in a patient who 
developed a high CTL response agaisnt the first virus has been described (Yang et al., 2005). 
Other authors  have suggested that the ability of the SI strain to overcome the preexisting 
immune response, is related to its ability to rapidly recombine in regions under immune 
pressure (Streeck et al., 2008).  
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4.2 Neutralization antibodies response 
Unlike CTL response, neutralization antibodies (NAbs) can prevent infection in animal 
models (Sealy et al., 2009), suggesting that this response might be able to prevent SI in 
humans. The lack of neutralizing antibody response was related with the predisposition to 
SI (Smith et al., 2006). On the contrary, a more extensive study showed that at the time of SI, 
there were not deficits in the Nabs response in the patients who became superinfected 
compared to the controls, concluding that NAbs elicited during natural infection was not 
sufficient to block infection (Blish et al., 2008).   
5. DI and disease progression 
Despite the varying disease progression rates, the majority of untreated HIV-infected 
individuals progress to AIDS in a period of around 10 years.  In some of the HIV-1 dual 
infected patients, an acelerated disease progression has been observed. In a cohort of 34 
patients, in the five individuals with dual infection, the progression to AIDS was very rapid 
(<3.4 years) (Gottlieb et al., 2004). SI with a dual tropic HIV-1 virus and rapid progression 
was reported (Gottlieb et al., 2007). In a cohort of HIV-1 subtype C infected female sex 
workers, DI was associated with an increase viral set point (Grobler et al., 2004). However is 
not clear whether SI leads allways to clinical progression  (Fung et al., 2010).   
6. SI in long term non progressor patients 
 It is very interesting to study SI in a special group of infected patients clasified as long term 
non progressor (LTNP) -a subset of HIV-positive individuals, who maintain high CD4+ T-
cell counts without therapy for more than 15 to 20 years- or in LTNP-Elite controllers (EC) 
who are LTNPs maintaining undectable viral loads. This group has attracted a lot of interest 
to disclose the factors contributing to the natural control of the viral replication. Viral 
control appears to be mediated by multiple mechanism including virological, host genetic 
and immune response factor: 
a. Virological factors 
Some studies supported that mutations or deletions in HIV functional proteins or in the 
accessory genes can lead to viral control like in the virus from the Sidney Cohort (Learmont 
et al., 1992). Recently, lower replicative capacity and reduced entry capacity in virus 
obtained from elite controller patients have been reported (Lassen et al., 2009). Other works 
attribute an important role to the impaired replicative capacity of gag (Miura et al., 2009) and 
pol regions obtained from these patients (Brumme et al., 2011). In addition, the presence of 
viruses with reduced replicative capacity in the initial stages of the infection has been 
described (Miura et al., 2010). In contrast, other authors did not find relevant deletions or 
defects after analyzing viral sequences from a large cohort of EC (Miura et al., 2007). 
Replication competent viruses, which replicated like standard laboratory strains “in vitro”, 
were obtained in 4 out of 10 ES patients,  (Blankson et al., 2007). Similar results were 
obtained by (Lamine et al., 2007) discarding the role of virological factors in the disease 
control in these patients. 
b. Host genetic 
Host genetic polymorphisms mapping in the coding and the promoter regions of the co-
receptor CCR5 have also been associated with protection against HIV-1 (Gonzalez et al., 
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1999). However, the most relevant host factor associated with viral control in HIV infected 
individuals is the presence of certain major histocompatibility complex class (MHC) I group 
B HLA I alleles (Deeks and Walker, 2007). HLA B* 57, B* 27 and B* 58 haplotypes are 
consistently overrepresented in these patients (Fellay et al., 2009; Migueles et al., 2000) .  
c. Immune response 
One of the most effective mechanisms to control HIV-1 infection is the CD8+T cell response. 
The effectiveness of the cytotoxic T-lymphocyte (CTL) response does not appear, however, 
to correlate to the number of the responsive cells but with its functionality (multiple 
cytokines secretion, degranulation, the ability to proliferate upon to encounter with HIV 
antigens) which is higher in controllers compared to non controllers (Hersperger et al.,2011). 
The maintenance of a robust HIV-specific CD4+ T cell response, providing help to CD8+T 
cells, may also help to the long term control of HIV replication as has been recently 
described (Blankson, 2010). 
Several investigations have studied if ECs have broadly neutralizing antibody (NAb) 
responses. It appears that this response is not present in most ECs and does not have a major 
protective role in the early or chronic phase of viral replication (Doria-Rose et al., 2010). 
 In the majority of the cases described in EC, SI is associated with loss of disease control. In a 
LTNP female sex worker, an abrupt decline in CD4T cells counts was associated to super-
infection (Fang et al., 2004). In two elite controller patients, an accelerated rate of disease 
progression was observed after a documented super-infection (Clerc et al., 2010). Control of 
disease after infection by a nef-defective strain is lost after SI by a fully competent virus in a 
B*57 HIV-1 LTNP patient (Braibant et al., 2010). However, other reports have stated SI in 
patients without apparent clinical consequences. Recovery of viremic control after SI in a 
long term elite controller patient has been also described although viral load was higher 
after SI, which implies that the patient did not fulfil the definition of elite controller 
(Rachinger et al., 2008). For the first time, SI in a long term EC patient able to control both 
viruses and maintain undetectable viral loads for > 20 years has been reported (Casado et 
al., 2007). This patient presented strong immune response and viruses with low “in vitro” 
replicative capacity (Pernas et al, manuscript in preparation).  
More studies of SI in people who control infection could be very useful in two ways: 
- - Understanding why some EC patients lost viral control after SI while others maintain 
their EC status.  
- - Analysis of SI in this group of patients could help to estimate the real incidence rate of 
SI in HIV natural infection, because in EC and LTNPS patients there is no or very little 
viral evolution (Wang et al., 2003), consequently less recombinant forms appear and the 
detection of SI should be easier than in the patients with typical progression. 
7. Conclusion 
The study of SI is a very productive topic in HIV research because it provides useful 
information for different aspects of HIV infection. SI patients constitute an interesting group 
of patients to investigate the role of the immune response generated against HIV infection 
and to investigate which factors, including host genes, contribute to protection against new 
infections. Also, the study of the phenotypic characteristics of the infecting and super-
infecting strains will produce very interesting information for HIV pathogenesis. Analysis of 
SI in LTNPs and EC patients could offer an excellent model for these studies. Moreover, 
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from the clinical perspective, detection of SI, with the potential pathogenic consequences, 
demonstrate  the importance of reducing risky behaviors in HIV-1 infected individuals. 
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